Feb 7, 2020 by Shannon Jones3 Biotech Companies AnalyzedWe examine three biotech companies' past performances and future outlooks.
Jul 19, 2019 by Shannon JonesLike Vanguard for Healthcare Costs: An Interview With HealthEquity CEO John KesslerHealthEquity's CEO explains how the company makes money while helping people tackle healthcare savings.
Jul 2, 2019 by Shannon Jones, Jason Moser, Dylan Lewis, and Nicholas ScipleBearish Signs and Antitrust TensionsThe Industry Focus hosts gather round the table to talk about (potentially) impending (short-term) doom for the market and big tech.
Jun 12, 2019 by Shannon Jones and Brian FeroldiThe Fastest-Growing Healthcare Company You've Never Heard OfThis medical device maker is growing rapidly and has already treated its investors to huge gains. Here's why Wall Street is so excited about where this company is heading.
May 31, 2018 by Shannon Jones2018 ASCO Conference RoundupAll your Motley Fool coverage of the 2018 ASCO Conference in one place.
Apr 26, 2018 by Shannon JonesA Promising Step for Medical MarijuanaMedical marijuana enthusiasts, get hyped -- GW Pharma’s advisory committee meeting results could mean huge things for the industry.
Apr 12, 2018 by Shannon JonesWhy One Drug Flop Tanked Incyte's StockBiotech is risky business, and Incyte shareholders have not had a good week after a key drug flopped its phase 3.
Aug 7, 2017 by Shannon JonesThese 3 Biotechs Just Crushed Analyst ExpectationsBut before you invest in any of them, you should read this.
Jul 25, 2017 by Shannon Jones3 Key Things Every CAR-T Investor Should WatchThe first CAR-T therapy recently won a unanimous thumbs up for approval. But that doesn't mean CAR-T stocks are out of the woods just yet.
Jun 21, 2016 by Shannon Jones3 Ways This $30 Billion Market Is Bristol's for the TakingHow this "Big Pharma" is revolutionizing the fight against cancer and well-positioned for long-term growth.
Apr 30, 2016 by Shannon Jones3 Key Pipeline Developments for Gilead Investors to WatchForget Hepatitis C -- here are 3 key developments investors should keep on their radars in 2016.
